Holen Sie sich die Stockscreener-App
65.62
0.20%
0.13
Handel nachbörslich:
65.62
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$65.49
Offen:
$65.26
24-Stunden-Volumen:
4.68M
Relative Volume:
0.75
Marktkapitalisierung:
$25.59B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
45.94
EPS:
1.4285
Netto-Cashflow:
$570.80M
1W Leistung:
+3.31%
1M Leistung:
+19.31%
6M Leistung:
-24.29%
1J Leistung:
-15.57%
1-Tages-Spanne:
$64.00
$66.04
1-Wochen-Bereich:
$64.00
$66.75
52-Wochen-Spanne:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
65.62 | 25.54B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
122.09 | 217.50B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
93.84 | 144.57B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.60 | 139.21B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.26 | 129.94B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.32 | 50.02B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
DEXCOM, INC. (NASDAQ: DXCM) SHAREHOLDER ALERT Bernstein - GlobeNewswire
DexCom, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your RightsDXCM - PR Newswire
DexCom, Inc. (DXCM) Shareholders Get Answers in Latest SueWallSt Podcast - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky to Join Class Action Before December 26, 2025 - Stockhouse
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - GlobeNewswire Inc.
Is DexCom Stock Underperforming the S&P 500? - MSN
DXCM SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc. (DXCM) - PR Newswire
Shareholders SueWallSt in New Class Action Against DexCom, Inc.Act Now - Nasdaq
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
Lowey Dannenberg Notifies DexCom, Inc. (“DexCom” or the - GlobeNewswire
SueWallSt Podcast Series Launches With Focus on DexCom, Inc. (DXCM) Fraud Allegations - ACCESS Newswire
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DexCom, Inc. $DXCM Shares Acquired by Marshall Wace LLP - MarketBeat
How DexCom Inc. (DC4) stock trades after rate cutsJuly 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Baird Financial Group Inc. Sells 49,243 Shares of DexCom, Inc. $DXCM - Defense World
Is DexCom Inc. (DC4) stock cheap by valuation metricsQuarterly Profit Review & Daily Oversold Bounce Ideas - Newser
Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth - GlobeNewswire
Key facts: Class Action Filed Against DexCom; Company Launches Academy - TradingView
Edgestream Partners L.P. Increases Position in DexCom, Inc. $DXCM - Defense World
Listening to healthcare professionals: Dexcom launches new education offering, Dexcom Academy - marketscreener.com
Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy - Eagle-Tribune
Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations - Nasdaq
The Gross Law Firm Notifies Shareholders of DexCom, - GlobeNewswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Isthmus Partners LLC Takes $14.61 Million Position in DexCom, Inc. $DXCM - MarketBeat
Groupe la Francaise Increases Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Fisher Asset Management LLC Decreases Holdings in DexCom, Inc. $DXCM - MarketBeat
How DexCom Inc. (DC4) stock trades after earnings2025 Earnings Surprises & High Return Stock Watch Alerts - Newser
DXCM DEADLINE: DexCom, Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Looming Deadline in Lawsuit - ACCESS Newswire
Morgan Stanley Upgrades DexCom (DXCM) - Nasdaq
DXCM DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, - GlobeNewswire
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
DexCom (DXCM): Morgan Stanley Upgrades Rating to Overweight and - GuruFocus
DexCom Stock Upgraded. How the Glucose Monitor Maker Is ‘Turning a Corner.’ - Barron's
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DexCom (DXCM) Upgraded by Morgan Stanley with Increased Price Ta - GuruFocus
DexCom upgraded at Morgan Stanley on sorting out operational issues - Seeking Alpha
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom LawsuitDXCM - PR Newswire
XTX Topco Ltd Lowers Stock Position in DexCom, Inc. $DXCM - MarketBeat
Analyst recommendations: Albemarle, Dexcom, T-Mobile, Alphabet, Micron… - marketscreener.com
Morgan Stanley Upgrades DexCom to Overweight From Equalweight, Adjusts PT to $75 From $63 - marketscreener.com
Advisors Asset Management Inc. Sells 1,259 Shares of DexCom, Inc. $DXCM - Defense World
DexCom, Inc. Sued for Securities Law Violations – Investors - GlobeNewswire
DexCom, Inc. Class Action: The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - PR Newswire
Vinva Investment Management Ltd Buys Shares of 6,994 DexCom, Inc. $DXCM - MarketBeat
Mackenzie Financial Corp Trims Stake in DexCom, Inc. $DXCM - MarketBeat
State Board of Administration of Florida Retirement System Has $33.95 Million Position in DexCom, Inc. $DXCM - MarketBeat
Global Retirement Partners LLC Takes $472,000 Position in DexCom, Inc. $DXCM - MarketBeat
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):